Journal of International Oncology››2020,Vol. 47››Issue (9): 573-576.doi:10.3760/cma.j.cn371439-20200611-00081
Received:2020-06-11Revised:2020-08-06Online:2020-09-08Published:2020-10-27
"
| 临床特征 | 例数(%) | |
|---|---|---|
| 性别 | ||
| 男 | 27(79.4) | |
| 女 | 7(20.6) | |
| ECOG评分 | ||
| 0 | 7(20.6) | |
| 1 | 24(70.6) | |
| 2 | 3(8.8) | |
| 既往吸烟史 | ||
| 有 | 20(58.8) | |
| 无 | 14(41.2) | |
| 病理类型 | ||
| 鳞状细胞癌 | 10(29.4) | |
| 非鳞状细胞癌 | 24(70.6) | |
| TNM分期 | ||
| Ⅲ期 | 9(26.5) | |
| Ⅳ期 | 25(73.5) | |
| 脑转移 | ||
| 有 | 4(11.8) | |
| 无 | 30(88.2) | |
| 骨转移 | ||
| 有 | 14(41.2) | |
| 无 | 20(58.8) | |
| 治疗时机 | ||
| 二线 | 25(73.5) | |
| 二线以上 | 9(26.5) | |
| 长春瑞滨节拍化疗用法 | ||
| 20 mg,1次/d | 20(58.8) | |
| 40 mg,3次/周 | 14(41.2) | |
| 其他第三代化疗药物 | ||
| 培美曲塞 | 11(32.4) | |
| 多西他赛 | 11(32.4) | |
| 紫杉醇脂质体 | 12(35.3) | |
"
"
"
| 不良反应 | 1~5级 | ≥3级 |
|---|---|---|
| 血液学毒性 | ||
| 白细胞减少 | 7(20.59) | 3(8.82) |
| 中性粒细胞减少 | 11(32.35) | 5(14.71) |
| 贫血 | 5(14.71) | 0(0) |
| 血小板减少 | 2(5.88) | 1(2.94) |
| 消化道毒性 | ||
| 恶心 | 9(26.47) | 3(8.82) |
| 呕吐 | 4(11.76) | 1(2.94) |
| 腹泻 | 4(11.76) | 1(2.94) |
| 便秘 | 3(8.82) | 0(0) |
| 肝毒性 | ||
| 谷丙转氨酶升高 | 9(26.47) | 0(0) |
| 谷草转氨酶升高 | 5(14.71) | 0(0) |
| 肾毒性 | ||
| 肌酐升高 | 0(0) | 0(0) |
| 尿素氮升高 | 1(2.94) | 0(0) |
| 心脏毒性 | 2(5.88) | 0(0) |
| 疲劳 | 8(23.53) | 1(2.94) |
| 其他 | 4(11.76) | 0(0) |
| [1] | Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009,27(11):1836-1843. DOI: 10.1200/JCO.2008.17.5844. doi:10.1200/JCO.2008.17.5844pmid:19273711 |
| [2] | Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development[J]. Future Oncol, 2016,12(3):373-387. DOI: 10.2217/fon.15.306. doi:10.2217/fon.15.306pmid:26584409 |
| [3] | Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004,22(9):1589-1597. DOI: 10.1200/JCO.2004.08.163. doi:10.1200/JCO.2004.08.163pmid:15117980 |
| [4] | Qi WX, Tang LN, He AN, et al. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2012,138(5):745-751. DOI: 10.1007/s00432-012-1155-9. pmid:22258853 |
| [5] | Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000,105(8):1045-1047. DOI: 10.1172/JCI9872. doi:10.1172/JCI9872pmid:10772648 |
| [6] | Kontopodis E, Hatzidaki D, Varthalitis I, et al. A phase Ⅱ study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase Ⅱ study of the Hellenic Oncology Research Group[J]. J Chemother, 2013,25(1):49-55. DOI: 10.1179/1973947812Y.0000000050. pmid:23433445 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
